GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Assertio Holdings Inc (NAS:ASRT) » Definitions » Gross Profit

Assertio Holdings (Assertio Holdings) Gross Profit : $109.3 Mil (TTM As of Mar. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Assertio Holdings Gross Profit?

Assertio Holdings's gross profit for the three months ended in Mar. 2024 was $21.3 Mil. Assertio Holdings's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $109.3 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Assertio Holdings's gross profit for the three months ended in Mar. 2024 was $21.3 Mil. Assertio Holdings's Revenue for the three months ended in Mar. 2024 was $32.4 Mil. Therefore, Assertio Holdings's Gross Margin % for the quarter that ended in Mar. 2024 was 65.55%.

Assertio Holdings had a gross margin of 65.55% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Assertio Holdings was 96.12%. The lowest was 76.96%. And the median was 83.99%.

Warning Sign:

Assertio Holdings Inc gross margin has been in long-term decline. The average rate of decline per year is -2.5%.


Assertio Holdings Gross Profit Historical Data

The historical data trend for Assertio Holdings's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assertio Holdings Gross Profit Chart

Assertio Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 220.00 86.40 95.18 137.49 125.05

Assertio Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.00 36.22 28.57 23.26 21.27

Competitive Comparison of Assertio Holdings's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Assertio Holdings's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Assertio Holdings's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Assertio Holdings's Gross Profit distribution charts can be found below:

* The bar in red indicates where Assertio Holdings's Gross Profit falls into.



Assertio Holdings Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Assertio Holdings's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=152.069 - 27.02
=125.0

Assertio Holdings's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=32.448 - 11.177
=21.3

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $109.3 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Assertio Holdings's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=21.3 / 32.448
=65.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Assertio Holdings  (NAS:ASRT) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Assertio Holdings had a gross margin of 65.55% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Assertio Holdings Gross Profit Related Terms

Thank you for viewing the detailed overview of Assertio Holdings's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Assertio Holdings (Assertio Holdings) Business Description

Traded in Other Exchanges
N/A
Address
100 South Saunders Road, Suite 300, Lake Forest, IL, USA, 60045
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Executives
Daniel A. Peisert director, officer: President & CEO C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Paul Schwichtenberg officer: SVP and CFO 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Ajay Patel officer: SVP and CAO 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Sam Schlessinger officer: SVP, General Counsel 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FORREST IL 60045
William Mckee director
Jeff L Vacirca director 4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121
Heather L Mason director 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
James L Tyree director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
Crg Partners Iii - Parallel Fund (a) L.p. 10 percent owner C/O CAPITAL ROYALTY L.P., 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Mark Strobeck officer: EVP & Chief Operating Officer 460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Crg Partners Iii L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Cr Group L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Andrea Heslin Smiley director 600 LEE ROAD, SUITE 100, WAYNE PA 19087
Megan C. Timmins officer: SVP, Gen Csl & Sec 600 LEE ROAD, SUITE 100, WAYNE PA 19087
Crg Partners Iii - Parallel Fund B (cayman) L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002

Assertio Holdings (Assertio Holdings) Headlines

From GuruFocus